Research map: Balancing sample size and accuracy of dose selection in phase 1 oncology trials – designs tiered by cohort size and maximum number of patients treated per dose

Back to the article

Papers in this map

  1. Optimal two-stage designs for phase II clinical trials · Richard M Simon · 1989 · 3668 citations · Cited by this paper
  2. Statistical approaches to classify investigational product using hERG safety assay · 2026 · Related
  3. Why 90% of clinical drug development fails and how to improve it? · Duxin Sun · 2022 · 1758 citations · Cited by this paper
  4. Advances in statistical methodologies for assessing bioequivalence of topical dermatological products · 2026 · Related
  5. Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer · John O’Quigley · 1990 · 1590 citations · Cited by this paper
  6. Real-world data and evidence in the development of cell and gene therapies · 2026 · Related
  7. Dose Escalation Methods in Phase I Cancer Clinical Trials · Christophe Le Tourneau · 2009 · 879 citations · Cited by this paper
  8. Robust CATE estimation using novel ensemble methods · 2026 · Related
  9. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results · Thomas J. Hwang · 2016 · 462 citations · Cited by this paper
  10. Augmented match weighted estimators: new methods for estimating average treatment effects under extreme propensity scores · 2026 · Related
  11. Critical aspects of the Bayesian approach to phase I cancer trials · Beat E. Neuenschwander · 2008 · 444 citations · Cited by this paper
  12. Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes · 2026 · Related
  13. Continual Reassessment Method: A Likelihood Approach · John O’Quigley · 1996 · 377 citations · Cited by this paper
  14. Non-inferiority testing for the odds ratio in two independent binomial proportions using the method of variance estimates recovery · 2026 · Related
  15. Bayesian optimal interval designs for phase I clinical trials · Suyu Liu · 2014 · 351 citations · Cited by this paper
  16. Bayesian quantitative decision-making framework in cell and gene therapy development for rare diseases · 2026 · Related
  17. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials · Ying Yuan · 2016 · 238 citations · Cited by this paper
  18. Analyze paired case–control data prospectively in comparing two predictive values · 2026 · Related
  19. Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012 · Leonard V. Sacks · 2014 · 220 citations · Cited by this paper
  20. Parallelism of four-parameter logistic bioassay models: equivalence testing for parameter differences* · 2026 · Related
  21. Dose Finding by the Continual Reassessment Method · Ying Kuen Cheung · 2011 · 208 citations · Cited by this paper
  22. An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics · Patricia Mucci LoRusso · 2010 · 121 citations · Cited by this paper
  23. Moving Beyond 3+3: The Future of Clinical Trial Design · Razelle Kurzrock · 2021 · 112 citations · Cited by this paper
  24. Phase I clinical trial designs in oncology: A systematic literature review from 2020 to 2022 · Ning Li · 2024 · 11 citations · Cited by this paper
  25. Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials · Ping Gao · 2023 · 3 citations · Cited by this paper
  26. Adaptive two-stage seamless sequential design for clinical trials · Ping Gao · 2024 · 3 citations · Cited by this paper
  27. Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon’s design · Ping Gao · 2024 · 1 citation · Cited by this paper
  28. Untitled · Cited by this paper
  29. Untitled · Cited by this paper
  30. Untitled · Cited by this paper

Source: OpenAlex (CC0)